Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)

被引：0
|
作者：
Mina M. Swiha
Duncan E. K. Sutherland
Golmehr Sistani
Alireza Khatami
Rami M. Abazid
Amol Mujoomdar
Daniele P. Wiseman
Jonathan G. Romsa
Robert H. Reid
David T. Laidley
机构：
[1] University of Western Ontario,Medical Imaging Department, Division of Nuclear Medicine, Victoria Hospital, London Health Sciences Centre
[2] University of Western Ontario,Medical Imaging Department, Division of Diagnostic Radiology
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
Survival predictors; Prognostic factors; Lu-Dotatate; PRRT; Neuroendocrine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 236
页数：11
相关论文
共 50 条
  • [1] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [2] Validation of a Clinical Score (CS) for Patients With Well-Differentiated Neuroendocrine Tumors (WD NETs) Under Consideration for Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Dotatate
    Das, Satya
    Chauhan, Aman
    Du, Liping
    Thomas, Katharine E.
    Jacob, Aasems
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana B.
    Ciombor, Kristen K.
    Goff, Laura W.
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin
    Berlin, Jordan
    Ramirez, Robert A.
    [J]. PANCREAS, 2022, 51 (03) : E41 - E41
  • [3] A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.
    Das, Satya
    Du Liping
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana Backlund
    Ciombor, Kristen Keon
    Goff, Laura Williams
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin P.
    Berlin, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [4] Combined use of 177Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study
    Fu, Jingjing
    Qiu, Fan
    Stolniceanu, Cati Raluca
    Yu, Fei
    Zang, Shiming
    Xiang, Yili
    Huang, Yue
    Matovic, Milovan
    Stefanescu, Cipriana
    Tang, Qiyun
    Wang, Feng
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (04)
  • [5] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [6] The role of 177Lu-Dotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastrointestinal neuroendocrine tumors (GI-NETs)
    Severi, S.
    Sansovini, M.
    Ambrosetti, A.
    Ianniello, A.
    Scarpi, E.
    Nanni, O.
    Sarnelli, A.
    Di Iorio, V.
    Garaboldi, L.
    Matteucci, F.
    Bartolomei, M.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S233 - S233
  • [7] Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.
    Das, Satya
    Chauhan, Aman
    Du, Liping
    Thomas, Katharine
    Jacob, Aasems
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana Backlund
    Ciombor, Kristen Keon
    Goff, Laura Williams
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin P.
    Berlin, Jordan
    Ramirez, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [9] Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)
    Badawy, Mohmed
    Johnson, Geoffrey B.
    Hobday, Timothy
    Packard, Annie T.
    Jain, Manoj
    Halfdanarson, Thorvardur R.
    Young, Jason R.
    Thorpe, Matthew P.
    Eiring, Rachel A.
    Kendi, Ayse Tuba
    [J]. PANCREAS, 2022, 51 (03) : E42 - E42
  • [10] Long-Term Follow-Up of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
    Sansovini, M.
    Severi, S.
    Nicolini, S.
    Ianniello, A.
    Ambrosetti, A.
    Cingarlini, S.
    Bongiovanni, A.
    Scarpi, E.
    Monti, M.
    Di Iorio, V
    Mezzenga, E.
    Paganelli, G.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 94 - 95
12345